Buxbaum James L, Eloubeidi Mohamad A
JOP. 2010 Nov 9;11(6):536-44.
Pancreas cancer has the worst prognosis of any solid tumor but is potentially treatable if it is diagnosed at an early stage. Thus there is critical interest in delineating clinical and molecular markers of incipient disease. The currently available biomarker, CA 19-9, has an inadequate sensitivity and specificity to achieve this objective. Diabetes mellitus, tobacco use, and chronic pancreatitis are associated with pancreas cancer. However, screening is currently only recommended in those with hereditary pancreatitis and genetic syndromes which predispose to cancer. Ongoing work to identify early markers of pancreas cancer consists of high throughput discovery methods including gene arrays and proteomics as well as hypothesis driven methods. While several promising candidates have been identified none has yet been convincingly proven to be better than CA 19-9. New methods including endoscopic ultrasound are improving detection of pancreas cancer and are being used to acquire tissue for biomarker discovery.
胰腺癌是所有实体瘤中预后最差的，但如果在早期阶段被诊断出来，它是有可能得到治疗的。因此，确定早期疾病的临床和分子标志物具有至关重要的意义。目前可用的生物标志物CA 19-9，其敏感性和特异性不足以实现这一目标。糖尿病、吸烟和慢性胰腺炎都与胰腺癌有关。然而，目前仅建议对患有遗传性胰腺炎和易患癌症的遗传综合征的人群进行筛查。正在进行的识别胰腺癌早期标志物的工作包括高通量发现方法，如基因阵列和蛋白质组学，以及基于假设的方法。虽然已经确定了几个有前景的候选标志物，但尚未有令人信服的证据表明它们比CA 19-9更好。包括内镜超声在内的新方法正在改善胰腺癌的检测，并被用于获取组织以发现生物标志物。
